Although we evaluated cancer incidence in patients receiving long-term TNF inhibitor therapy and identified characteristics associated with cancer occurrence, a direct comparison with sex- and age-matched TNF inhibitor-naïve patients or with the general population would be required to determine whether the incidence is truly higher or lower and whether TNF inhibitor use itself influences risk. This evidence concerns the gene TNF and cancer.